Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Novel Treatment Options for Adults With COVID-19 Pneumonia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥18 years of age~* Confirmed COVID-19 infection by presence of SARS-CoV-2 nucleic acid by polymerase chain reaction (PCR)~* Evidence of pneumonia given by at least one of the following: SpO2 ≤93% on ambient air or PaO2/FiO2 \<300 mmHg/40 kPa OR Radiographic findings compatible with COVID-19 pneumonia~* For women of childbearing potential: Negative pregnancy test and willingness to use contraceptive (consistent with local regulations) during study period~* Signed Informed Consent Form by any patient capable of giving consent, or, when the patient is not capable of giving consent, by his or her legal/authorized representatives~Exclusion Criteria:~* In the opinion of the investigator, progression to death is imminent and inevitable within the next 24 hours, irrespective of the provision of treatment~* Participating in other drug clinical trials (participation in COVID-19 antiviral trials may be permitted if approved by sponsor)\*~* Pregnant or breastfeeding, positive pregnancy test in a pre-dose examination~* Any serious medical condition or abnormality of clinical laboratory tests that, in the investigator's judgment, precludes the patient's safe participation in and completion of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Convalescent plasma (Type: ACTIVE_COMPARATOR): Will receive active treatment with convalescent anti-SARS-CoV-2 plasma (600 ml) as a single dose iv infusion in addition to standard care.
- Infusion placebo (Type: PLACEBO_COMPARATOR): Will receive placebo treatment with saline 0.9% (2 x 300 ml) as an iv single dose infusion in addition to standard care.

Based on this trial design, predict the completion outcome and termination type (if applicable).